BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34024743)

  • 1. Combining Stereotactic Body Radiotherapy and Microwave Ablation Appears Safe and Feasible for Renal Cell Carcinoma in an Early Series.
    Blitzer GC; Wojcieszynski A; Abel EJ; Best S; Lee FT; Hinshaw JL; Wells S; Ziemlewicz TJ; Lubner MG; Alexander M; Yadav P; Bayouth JE; Floberg J; Cooley G; Harari PM; Bassetti MF
    Clin Genitourin Cancer; 2021 Oct; 19(5):e313-e318. PubMed ID: 34024743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic Body Radiotherapy for Stage I Renal Cell Carcinoma: National Treatment Trends and Outcomes Compared to Partial Nephrectomy and Thermal Ablation.
    Uhlig A; Uhlig J; Trojan L; Kim HS
    J Vasc Interv Radiol; 2020 Apr; 31(4):564-571. PubMed ID: 32127324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
    Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
    Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost Effectiveness Analysis of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) for Early Stage Renal Cell Carcinoma (RCC).
    Donovan EK; Xie F; Louie AV; Chu W; Siva S; Kapoor A; Swaminath A
    Clin Genitourin Cancer; 2022 Oct; 20(5):e353-e361. PubMed ID: 35490099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic body radiotherapy for inoperable patients with renal carcinoma.
    Kotzki L; Udrescu C; Lapierre A; Badet L; Rouviere O; Paparel P; Chapet O
    Fr J Urol; 2024 Mar; 34(2):102575. PubMed ID: 38364353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiofrequency Ablation, Cryoablation, and Microwave Ablation for T1a Renal Cell Carcinoma: A Comparative Evaluation of Therapeutic and Renal Function Outcomes.
    Zhou W; Herwald SE; McCarthy C; Uppot RN; Arellano RS
    J Vasc Interv Radiol; 2019 Jul; 30(7):1035-1042. PubMed ID: 30956075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic Ablative Radiotherapy for ≥T1b Primary Renal Cell Carcinoma: A Report From the International Radiosurgery Oncology Consortium for Kidney (IROCK).
    Siva S; Correa RJM; Warner A; Staehler M; Ellis RJ; Ponsky L; Kaplan ID; Mahadevan A; Chu W; Gandhidasan S; Swaminath A; Onishi H; Teh BS; Lo SS; Muacevic A; Louie AV
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):941-949. PubMed ID: 32562838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma.
    Grubb WR; Ponsky L; Lo SS; Kharouta M; Traughber B; Sandstrom K; MacLennan GT; Shankar E; Gupta S; Machtay M; Ellis RJ
    Radiother Oncol; 2021 Feb; 155():138-143. PubMed ID: 33214131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Assessment of Chronic Kidney Disease following Microwave Ablation for Stage T1 Renal Cell Carcinoma.
    Zhou W; Herwald SE; Uppot RN; Arellano RS
    J Vasc Interv Radiol; 2018 Dec; 29(12):1685-1691. PubMed ID: 30297311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing Outcomes for Patients with Clinical T1b Renal Cell Carcinoma Treated With Either Percutaneous Microwave Ablation or Surgery.
    Shapiro DD; Wells SA; Best SL; Hedican SP; Ziemlewicz TJ; Lubner MG; Hinshaw JL; Lee FT; Jarrard DF; Richards KA; Downs TM; Allen GO; Nakada SY; Abel EJ
    Urology; 2020 Jan; 135():88-94. PubMed ID: 31585198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
    Correa RJM; Louie AV; Zaorsky NG; Lehrer EJ; Ellis R; Ponsky L; Kaplan I; Mahadevan A; Chu W; Swaminath A; Hannan R; Onishi H; Teh BS; Muacevic A; Lo SS; Staehler M; Siva S
    Eur Urol Focus; 2019 Nov; 5(6):958-969. PubMed ID: 31248849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation therapy options in kidney cancer.
    Zaorsky NG; Louie AV; Siva S
    Curr Opin Support Palliat Care; 2023 Dec; 17(4):308-314. PubMed ID: 37877449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-powered microwave ablation of t1a renal cell carcinoma: safety and initial clinical evaluation.
    Moreland AJ; Ziemlewicz TJ; Best SL; Hinshaw JL; Lubner MG; Alexander ML; Brace CL; Kitchin DR; Hedican SP; Nakada SY; Lee FT; Abel EJ
    J Endourol; 2014 Sep; 28(9):1046-52. PubMed ID: 24846329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma.
    Ponsky L; Lo SS; Zhang Y; Schluchter M; Liu Y; Patel R; Abouassaly R; Welford S; Gulani V; Haaga JR; Machtay M; Ellis RJ
    Radiother Oncol; 2015 Oct; 117(1):183-7. PubMed ID: 26362723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?
    Amini A; Altoos B; Bourlon MT; Bedrick E; Bhatia S; Kessler ER; Flaig TW; Fisher CM; Kavanagh BD; Lam ET; Karam SD
    Pract Radiat Oncol; 2015; 5(6):e589-e596. PubMed ID: 26142027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percutaneous microwave ablation of T1a and T1b renal cell carcinoma: short-term efficacy and complications with emphasis on tumor complexity and single session treatment.
    Wells SA; Wheeler KM; Mithqal A; Patel MS; Brace CL; Schenkman NS
    Abdom Radiol (NY); 2016 Jun; 41(6):1203-11. PubMed ID: 27167230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable control of locally recurrent renal cell carcinoma using stereotactic body radiotherapy.
    Maclean J; Breau RH; Scheida N; Malone S
    BMJ Case Rep; 2014 Sep; 2014():. PubMed ID: 25199199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer : Literature review and practice recommendations of the DEGRO Working Group on Stereotactic Radiotherapy.
    Panje C; Andratschke N; Brunner TB; Niyazi M; Guckenberger M
    Strahlenther Onkol; 2016 Dec; 192(12):875-885. PubMed ID: 27778052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-fraction stereotactic body radiotherapy for spinal metastases from renal cell carcinoma.
    Balagamwala EH; Angelov L; Koyfman SA; Suh JH; Reddy CA; Djemil T; Hunter GK; Xia P; Chao ST
    J Neurosurg Spine; 2012 Dec; 17(6):556-64. PubMed ID: 23020208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS).
    Siva S; Louie AV; Kotecha R; Barber MN; Ali M; Zhang Z; Guckenberger M; Kim MS; Scorsetti M; Tree AC; Slotman BJ; Sahgal A; Lo SS
    Lancet Oncol; 2024 Jan; 25(1):e18-e28. PubMed ID: 38181809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.